[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622976":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":24,"centralContacts":28,"locations":36,"responsibleParty":118,"collaborators":10,"id":120,"slug":10,"hasResults":121,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":10,"eligibilityCriteria":125,"healthyVolunteers":121,"sex":126,"minAge":127,"maxAge":10,"enrollmentInfo":128,"targetDuration":10,"studyType":131,"phases":10,"briefSummary":132,"conditions":133,"keywords":137,"overallStatus":39,"whyStopped":10,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":151},{"fullName":5,"class":6},"Memorial Sloan Kettering Cancer Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants With Urothelial Carcinoma",null,"Participants will have histological or cytologically confirmed urothelial carcinoma",[13,14],"Other: Non-therapeutic Nerve Conduction Studies","Other: Non-therapeutic assessment of patient-reported neuropathy",[16,20],{"type":6,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"Non-therapeutic Nerve Conduction Studies","Non-invasive nerve conduction studies (NCS) offer an objective, quantitative approach to assess peripheral nerve function, particularly in sensory fibers, which are most commonly affected in chemotherapy-induced peripheral neuropathy\u002FCIPN",[9],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"Non-therapeutic assessment of patient-reported neuropathy","To evaluate the incidence and severity of chemotherapy-induced peripheral neuropathy (CIPN) in participants receiving enfortumab vedotin, we will collect non-therapeutic, participant-reported outcomes",[9],[25],{"name":26,"affiliation":5,"role":27},"Samuel Funt, MD","PRINCIPAL_INVESTIGATOR",[29,33],{"name":26,"role":30,"phone":31,"phoneExt":10,"email":32},"CONTACT","646-888-4770","funts@mskcc.org",{"name":34,"role":30,"phone":35,"phoneExt":10,"email":10},"Gopakumar Iyer, MD","646-888-4717",[37,52,63,74,86,97,107],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Memorial Sloan Kettering Cancer Center Basking Ridge (Limited Protocol Activities)","RECRUITING","Basking Ridge","New Jersey","07920","United States",{"type":45,"coordinates":46},"Point",[47,48],-74.54932,40.70621,{"lat":48,"lon":47},[51],{"name":26,"role":30,"phone":31,"phoneExt":10,"email":10},{"facility":53,"status":39,"city":54,"state":41,"zip":55,"country":43,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"Memorial Sloan Kettering Monmouth (Limited Protocol Activities)","Middletown","07748",{"type":45,"coordinates":57},[58,59],-74.11709,40.39428,{"lat":59,"lon":58},[62],{"name":26,"role":30,"phone":31,"phoneExt":10,"email":10},{"facility":64,"status":39,"city":65,"state":41,"zip":66,"country":43,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"Memorial Sloan Kettering Bergen (Limited Protocol Activities)","Montvale","07645",{"type":45,"coordinates":68},[69,70],-74.02292,41.04676,{"lat":70,"lon":69},[73],{"name":26,"role":30,"phone":31,"phoneExt":10,"email":10},{"facility":75,"status":39,"city":76,"state":77,"zip":78,"country":43,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)","Commack","New York","11725",{"type":45,"coordinates":80},[81,82],-73.29289,40.84288,{"lat":82,"lon":81},[85],{"name":26,"role":30,"phone":31,"phoneExt":10,"email":10},{"facility":87,"status":39,"city":88,"state":77,"zip":89,"country":43,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"Memorial Sloan Kettering Westchester (Limited Protocol Activities)","Harrison","10604",{"type":45,"coordinates":91},[92,93],-73.71263,40.96899,{"lat":93,"lon":92},[96],{"name":26,"role":30,"phone":31,"phoneExt":10,"email":10},{"facility":98,"status":39,"city":77,"state":77,"zip":99,"country":43,"cosmosGeoPoint":100,"geoPoint":104,"contacts":105},"Memorial Sloan Kettering Cancer Center (All Protocol Activites)","10065",{"type":45,"coordinates":101},[102,103],-74.00597,40.71427,{"lat":103,"lon":102},[106],{"name":26,"role":30,"phone":31,"phoneExt":10,"email":10},{"facility":108,"status":39,"city":109,"state":77,"zip":110,"country":43,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"Memorial Sloan Kettering Nassau (Limited Protocol Activites)","Rockville Centre","11553",{"type":45,"coordinates":112},[113,114],-73.64124,40.65871,{"lat":114,"lon":113},[117],{"name":26,"role":30,"phone":31,"phoneExt":10,"email":10},{"type":119,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100622976",false,"NCT07390617","A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma","Interrogating Enfortumab Vedotin-associated Neuropathy in Patients With Metastatic or Muscle-Invasive Urothelial Carcinoma Receiving Enfortumab Vedotin","Inclusion Criteria:\n\n* Written informed consent by and HIPAA authorization for release of personal health information obtained from the research participant.\n* Able to speak and read English to a sufficient level of fluency to provide informed consent and complete the study questionnaires.\n* Age ≥ 18 years at the time of consent.\n* ECOG Performance Status of ≤ 3 within 28 days prior to consent.\n* Histological or cytologically confirmed urothelial carcinoma.\n* Patients must be planned to start systemic therapy with enfortumab vedotin\n* At time of enrollment, patients must be planned to start enfortumab with or without pembrolizumab\n\nExclusion Criteria:\n\nSubjects meeting any of the criteria below may not participate in the study:\n\n* Inability of the subject to understand and comply with study procedures.\n* Having previously received enfortumab vedotin\n* Students\u002Femployees of the study institution, pregnant women, prisoners, and institutionalized individuals (to prevent enrollment of vulnerable subjects).","ALL","18 Years",{"count":129,"type":130},50,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to see how results of nerve tests change in people with urothelial cancer who receive treatment with enfortumab vedotin (EV)",[134,135,136],"Neuropathy","Urothelial Carcinoma","Metastatic Urothelial Carcinoma",[138,139,140,5,141],"urothelial carcinoma","metastatic urothelial carcinoma","neuropathy","25-371","2026-05-26",{"date":144,"type":145},"2026-05-29","ACTUAL",{"date":147,"type":145},"2026-01-20",{"date":149,"type":130},"2028-01-20",{"name":5,"class":6},7]